• 1. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 2. Aggregation-induced chiroptical generation and photoinduced switching of achiral azobenzene-alt-fluorene copolymer endowed with left- and right-handed helical polysilanes?
  Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856
• 3. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

Recent Advances in the Synthesis and Applications of tert-Butyl 7-Hydroxy-4-azaspiro[2.5]octane-4-carboxylate (CAS: 2306269-68-9)

In recent years, the compound tert-butyl 7-hydroxy-4-azaspiro[2.5]octane-4-carboxylate (CAS: 2306269-68-9) has garnered significant attention in the field of chemical biology and pharmaceutical research. This spirocyclic compound, characterized by its unique structural features, has shown promising potential as a key intermediate in the synthesis of bioactive molecules and drug candidates. The presence of both a hydroxyl group and a tert-butyl carbamate moiety in its structure makes it a versatile building block for further chemical modifications, enabling the development of novel therapeutic agents.

Recent studies have focused on optimizing the synthetic routes for tert-butyl 7-hydroxy-4-azaspiro[2.5]octane-4-carboxylate to improve yield and scalability. One notable approach involves the use of catalytic asymmetric synthesis, which has demonstrated high enantioselectivity and efficiency. Researchers have also explored its applications in the construction of complex heterocyclic frameworks, which are prevalent in many FDA-approved drugs. The compound's ability to serve as a precursor for spirocyclic scaffolds has been particularly valuable in the design of kinase inhibitors and GPCR modulators.

In addition to its synthetic utility, tert-butyl 7-hydroxy-4-azaspiro[2.5]octane-4-carboxylate has been investigated for its biological activity. Preliminary in vitro studies suggest that derivatives of this compound exhibit moderate inhibitory effects against certain enzymes involved in inflammatory pathways. These findings have sparked interest in further exploring its potential as a lead compound for the development of anti-inflammatory and immunomodulatory agents. However, more extensive pharmacological evaluations are needed to fully elucidate its mechanism of action and therapeutic potential.

The pharmaceutical industry has also recognized the value of this compound in drug discovery programs. Several patent applications filed in the past two years highlight its use in the synthesis of proprietary drug candidates targeting neurological disorders and metabolic diseases. The compound's spirocyclic core is particularly advantageous for enhancing drug-like properties, such as solubility and metabolic stability, which are critical for successful drug development.

Despite these advancements, challenges remain in the large-scale production and purification of tert-butyl 7-hydroxy-4-azaspiro[2.5]octane-4-carboxylate. Researchers are actively working on addressing these issues through the development of greener synthetic methodologies and improved purification techniques. Future studies are expected to focus on expanding the scope of its applications, particularly in the realm of targeted drug delivery and personalized medicine.

In conclusion, tert-butyl 7-hydroxy-4-azaspiro[2.5]octane-4-carboxylate (CAS: 2306269-68-9) represents a promising scaffold in medicinal chemistry with diverse applications. Its unique structural features and synthetic versatility make it a valuable tool for drug discovery and development. Continued research efforts are likely to uncover new opportunities for leveraging this compound in the design of next-generation therapeutics.

• 929971-93-7(tert-butyl 8-hydroxy-5-azaspiro[3.5]nonane-5-carboxylate)
• 2166732-63-2(tert-butyl 2-hydroxy-6-azaspiro[4.5]decane-6-carboxylate)
• 870889-86-4(3-endo-Hydroxy-3-exo-methyl-8-azabicyclo[3.2.1]octane-8-carboxylic Acid t-Butyl Ester)
• 1502162-73-3(Tert-butyl 4-hydroxy-2,2-dimethylpiperidine-1-carboxylate)
• 2306271-27-0(tert-butyl 9-hydroxy-1-azaspiro[5.5]undecane-1-carboxylate)
• 870889-20-6((1R,3R,5S)-tert-Butyl3-hydroxy-3-methyl-8-azabicyclo3.2.1octane-8-carboxylate)
• 2361635-70-1(Tert-butyl 7-oxa-10-azadispiro[2.1.25.33]decane-10-carboxylate)
• 1934510-39-0(tert-butyl 2-hydroxy-5-azaspiro[3.5]nonane-5-carboxylate)
• 2306269-99-6(tert-butyl 6-(hydroxymethyl)-4-azaspiro[2.5]octane-4-carboxylate)
• 1544407-76-2(tert-butyl 5-hydroxy-2-azabicyclo[4.1.0]heptane-2-carboxylate)